[CLSTR]
< Back to situation

[REVISION HISTORY]

Philip Morris earnings, forecast cut, IQOS & Zyn growth

Updated 3 times since CLSTR started tracking revisions of this situation.

What changed

2026-07-28 11:29 UTC → 2026-07-31 22:52 UTC · added removed

In early July 2026, Philip Morris International reported posted first‑quarter earnings of $1.96 per share on $10.15 billion revenue, a 9.1% year‑on‑year increase, revenue and paid a $1.47 dividend. Two weeks later the reported second‑quarter results showed revenue of $11.2 billion net revenue, a 10.4% rise driven by an 11.7% jump in its billion, with the smoke‑free segment, now segment rising 11.7% to about 42% of sales across 109 markets. sales. Adjusted EPS climbed to reached $2.20, but the full‑year profit outlook was trimmed to $8.26‑$8.41 per share amid stronger competition in nicotine‑pouch products and adverse currency effects. PMI The company accelerated its U.S. Zyn portfolio, adding new 1.5 mg and 8 mg variants portfolio after FDA approval, and announced a doubled investment approval of new variants and, in late July, confirmed that its Aurora, Colorado campus to roughly will receive a $1.2 billion investment through 2028. 2028—double the original commitment. The 780,000‑square‑foot, 148‑acre greenfield facility facility, which began full commercial production in July 2026, producing will supply Zyn pouches for domestic consumption use and export to Asia, Latin America and the Caribbean. PMI projects an annual economic impact of about $550 million, Caribbean, creating roughly 500 direct and 1,000 indirect jobs. The Aurora plant joins existing nicotine‑product sites in Owensboro, Kentucky, jobs and Wilson, North Carolina. an estimated $550 million annual economic impact. IQOS continued to gain traction, market share, achieving a 21.5% off‑take share in global travel‑retail airports, up 3.1 points year‑on‑year. airports. Institutional activity included Clough Capital Partners acquiring roughly about 50,000 PMI shares. PMI’s CEO Jacek Olczak highlighted the momentum from the first half of the year and reaffirmed confidence in meeting annual targets. targets, while noting industry‑wide shifts toward next‑generation nicotine products, as reflected in comparable growth reported by British American Tobacco.

Versions

  1. 2026-07-31 22:52 UTC Philip Morris earnings, forecast cut, IQOS & Zyn growth
  2. 2026-07-28 11:29 UTC Philip Morris earnings, forecast cut, IQOS & Zyn growth
  3. 2026-07-28 10:11 UTC Philip Morris earnings, forecast cut, IQOS & Zyn growth
  4. 2026-07-27 12:34 UTC Philip Morris earnings, forecast cut, IQOS expansion

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.